VIA
ARQT icon

Virtus Investment Advisers’s Arcutis Biotherapeutics ARQT Stock Holding History

Virtus Investment Advisers’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.25M Buy
47,698
+18,606
+64% +$433K 0.29% 171
2026
Q1 		$685K Buy
29,092
+5,543
+24% +$141K 0.19% 181
2025
Q4 		$684K Buy
23,549
+15,120
+179% +$387K 0.19% 180
2025
Q3 		$159K Buy
8,429
+1,464
+21% +$23.1K 0.05% 366
2025
Q2 		$97.6K Sell
6,965
-6,436
-48% -$90.2K 0.03% 343
2025
Q1 		$210K Buy
+13,401
New +$189K 0.06% 260

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Virtus Investment Advisers's ARQT Position: Q2 2026 in Review

Virtus Investment Advisers increased its Arcutis Biotherapeutics (ARQT) stake by 64% in Q2 2026, buying an estimated $433K and bringing the position to 47,698 shares worth $1.25M. The position accounts for 0.29% of the portfolio, ranked #171.

Virtus Investment Advisers first reported a position in ARQT in Q1 2025 and has held it in 6 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Virtus Investment Advisers held 47,698 shares of Arcutis Biotherapeutics worth $1.25M as of Q2 2026.
  • Virtus Investment Advisers bought 18,606 Arcutis Biotherapeutics shares in Q2 2026, an estimated $433K.
  • Arcutis Biotherapeutics made up 0.29% of Virtus Investment Advisers's portfolio in Q2 2026, its #171 holding.
  • Virtus Investment Advisers first reported a position in Arcutis Biotherapeutics in Q1 2025 and has held it in 6 quarters since.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.